The Ephrin type-B receptor 4 (EPHB4), a receptor tyrosine kinase, is notably overexpressed in oral squamous cell carcinoma (OSCC), and this overexpression correlates with poor prognosis, making EPHB4 a broadly relevant target in HNSCC and a promising candidate for CAR-T cell therapy [32,33,34,35,36,37,38]. This evidence concerns the gene NTRK1 and head and neck squamous cell carcinoma.